Moodley M, Tunkyi K, Moodley J
Department of Obstetrics and Gynaecology, Nelson R Mandela School of Medicine, University of Natal, Durban, South Africa.
Int J Gynecol Cancer. 2003 Mar-Apr;13(2):234-9. doi: 10.1046/j.1525-1438.2003.13027.x.
Gestational trophoblastic disease (GTD) represents a spectrum of histologically distinct entities including molar pregnancy and choriocarcinoma. The incidence of GTD varies in different parts of the world with high incidences in countries like Japan (2 / 1000 pregnancies). With the advent of sensitive assays for detection of serum beta human chorionic gonadotrophin (HCG) and ultrasound, GTD can now be detected earlier in pregnancy. To date no studies have been reported from South Africa regarding the epidemiology, management, and outcome of patients with GTD. This study was a retrospective audit based on 112 patients with GTD treated at King Edward VIII Hospital, Durban, South Africa. Clinical records of patients were reviewed with regards to presentation, investigation, management and outcome. Of 112 patients, there were 78 patients (70%) with hydatidiform mole and 34 patients (30%) with choriocarcinoma. The mean age of patients was 28.5 years (SD 8.1 years). The majority of patients were Black females (94.6%) while 4.4% were Asian and 1% Coloured females. The most common presenting symptom was vaginal bleeding (93.8%). There were 74 patients (66.7%) who had a previous normal term pregnancy and only two patients (1.8%) had previous molar pregnancies. Suction curettage was the main treatment modality for patients with molar pregnancy while choriocarcinoma was treated primarily with chemotherapy. A total of 72 percent of patients with molar pregnancy and 28 percent with choriocarcinoma had complete remission after initial treatment. Twelve patients died during the course of treatment mainly due to late presentation and advanced metastatic disease. Complete cure was achieved in 89% of patients. Age, parity, previous history, initial uterine size, presence of theca-lutein cysts, and initial betaHCG concentration was not found to be prognostic for persistent trophoblastic disease. In the present study, the incidence of molar pregnancy and choriocarcinoma was 1.2 / 1000 and 0.5 / 1000 deliveries, respectively. This is much lower than those quoted from countries such as Japan. However, the incidence quoted from our study may be overestimated as this was a hospital-based study and most of the uncomplicated deliveries occur in referring centers. Only 20% of patients in this study were above the age of 35 years with a mean age of 28.5 years. The majority of patients were of Black African ethnic origin mainly due to the fact that our hospital is a referral center for Black patients. Similar to other studies, the majority of patients with molar pregnancy were treated with suction curettage while the majority of patients with choriocarcinoma were treated with chemotherapy. Overall, spontaneous remission was achieved in 60% of patients with molar pregnancy and an overall complete cure was achieved in 89% of patients.
妊娠滋养细胞疾病(GTD)是一组组织学上不同的疾病,包括葡萄胎妊娠和绒毛膜癌。GTD的发病率在世界不同地区有所不同,在日本等国家发病率较高(每1000例妊娠中有2例)。随着血清β人绒毛膜促性腺激素(HCG)检测和超声检查等敏感检测方法的出现,现在可以在妊娠早期检测到GTD。迄今为止,南非尚未有关于GTD患者的流行病学、管理和结局的研究报告。本研究是一项基于南非德班爱德华八世医院治疗的112例GTD患者的回顾性审计。回顾了患者的临床记录,包括临床表现、检查、管理和结局。112例患者中,78例(70%)为葡萄胎,34例(30%)为绒毛膜癌。患者的平均年龄为28.5岁(标准差8.1岁)。大多数患者为黑人女性(94.6%),而4.4%为亚洲女性,1%为混血女性。最常见的临床表现为阴道出血(93.8%)。74例患者(66.7%)既往有正常足月妊娠史,只有2例患者(1.8%)既往有葡萄胎妊娠史。吸刮术是葡萄胎妊娠患者的主要治疗方式,而绒毛膜癌主要采用化疗治疗。初次治疗后,72%的葡萄胎妊娠患者和28%的绒毛膜癌患者完全缓解。12例患者在治疗过程中死亡,主要原因是就诊延迟和晚期转移性疾病。89%的患者实现了完全治愈。未发现年龄、产次、既往史、初始子宫大小、黄素囊肿的存在以及初始βHCG浓度对持续性滋养细胞疾病具有预后意义。在本研究中,葡萄胎妊娠和绒毛膜癌的发病率分别为每1000例分娩中有1.2例和0.5例。这远低于日本等国家的报道。然而,我们研究中引用的发病率可能被高估了,因为这是一项基于医院的研究,大多数无并发症的分娩发生在转诊中心。本研究中只有20%的患者年龄超过35岁,平均年龄为28.5岁。大多数患者为非洲黑人族裔,主要是因为我们医院是黑人患者的转诊中心。与其他研究相似,大多数葡萄胎妊娠患者接受了吸刮术治疗,而大多数绒毛膜癌患者接受了化疗治疗。总体而言,60%的葡萄胎妊娠患者实现了自发缓解,89%的患者实现了总体完全治愈。